MAST Biosurgery Revenue and Competitors
Estimated Revenue & Valuation
- MAST Biosurgery's estimated annual revenue is currently $5.8M per year.
- MAST Biosurgery's estimated revenue per employee is $251,000
Employee Data
- MAST Biosurgery has 23 Employees.
- MAST Biosurgery grew their employee count by -34% last year.
MAST Biosurgery's People
Name | Title | Email/Phone |
---|---|---|
1 | Director U.S. Sales & Director Sales Training | Reveal Email/Phone |
2 | Sales Manager | Reveal Email/Phone |
3 | Mechanical Engineer | Reveal Email/Phone |
4 | Document Control Specialist/QC Inspector | Reveal Email/Phone |
MAST Biosurgery Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is MAST Biosurgery?
Leading in the design, development, and production of bioresorbable polymer implants, and emerging new technologies for the use in variety of surgical applications within the biosurgery market. Before the advent of bioresorbable materials, the closure of soft tissue was limited to permanent materials such as nylon sutures. Advances in material sciences led to the development of bioresorbable polymer sutures that met the clinical needs of holding soft tissues together, while serving the patient's need of not remaining permanently in the body. The evolution of bioresorbable polymer technology facilitated the development of large bioresorbable polymer sheets that could span large tissue masses and subsequently hold them in place. The thin sheets facilitate the healing of larger tissue masses and virtually eliminating many adverse effects of permanent implants. Bioresorbable surgical thin sheet for soft tissue applications, made from polylactide (PLA): a copolymer of 70:30 Poly(L-lactide-co-D,L-lactide). Composed of lactic acid similar to that which occurs naturally in the human body, the copolymer maintains its strength during the healing process, and through hydrolysis slowly breaks down into lactic acid molecules. The molecules are ultimately metabolized into carbon dioxide and water and are released from the body through the lungs.
keywords:N/AN/A
Total Funding
23
Number of Employees
$5.8M
Revenue (est)
-34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.3M | 23 | -8% | N/A |
#2 | $3.4M | 23 | 21% | N/A |
#3 | $2.3M | 23 | N/A | N/A |
#4 | $4M | 23 | -21% | $74.4M |
#5 | $2.4M | 23 | 5% | N/A |